ArticleProbiotics and antimicrobial proteins2026
Prediction of Chemically Modified Antimicrobial Peptides and Their Sub-functional Activities Using Hybrid Features.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Intelligence-Driven Discovery and Optimization of Antimicrobial Peptides Targeting ESKAPE Pathogens and Multidrug-Resistant Fungi.Microorganisms · 2026Review
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) demonstrate a broad spectrum of activities against various pathogens, thereby offering a promising strategy to mitigate the urgent challenge of antimicrobial resistance. Recent studies indicate that chemically modified AMPs (cmAMPs), which contain chemically modified amino acids, have the potential to alleviate the adverse effects commonly associated with conventional AMPs. Nevertheless, there remains a notable deficiency in computational methods specifically designed for the analysis and prediction of cmAMPs and their sub-function predictions. In this study, we proposed a two-layer model, termed as iCMAMP, aimed for the identification of cmAMPs and their sub-functional activities. The first layer, referred to as iCMAMP-1L, integrates three categories encompassing seven distinct groups of features, in conjunction with an ensemble method designed at enhancing predictive accuracy for cmAMPs. This ensemble approach effectively extracts relevant insights from a heterogeneous array of features sets while addressing potential dimensionality challenges. On the test dataset, iCMAMP-1L achieved an ACC of 0.934 and an MCC of 0.868, representing improvements of 3.4% and 6.8%, respectively, over AntiMPmod, which is the sole existing method for predicting cmAMPs. A comparative analysis between cmAMPs and their corresponding AMPs revealed that chemical modifications can significantly reduce hemolysis and toxicity associated with AMPs, while the functional characteristics of the peptides are primarily determined by their sequences. The second layer of our model, designated as iCMAMP-2L, employed a multi-label classification approach to predict the sub-functional activities of cmAMPs, with a specific focus on the dipeptide composition-based features. On the test dataset, iCMAMP-2L achieved an Accuracy of 0.390 and an Absolute true of 0.621. The data and Python code used in the iCMAMP model are available at https://github.com/swicher123/iCMAMP/tree/master .
Indexed as
Identifiers
40397268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.